Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas

作者：Alentorn Agusti; Dehais Caroline; Ducray Francois; Carpentier Catherine; Mokhtari Karima; Figarella Branger Dominique; Chinot Olivier; Cohen Moyal Elisabeth; Ramirez Carole; Loiseau Hugues; Elouahdani Hamdi Selma; Beauchesne Patrick; Langlois Olivier; Desenclos Christine; Guillamo Jean Sebastien; Dam Hieu Phong; Ghiringhelli Francois; Colin Philippe; Godard Joel; Parker Fabrice; Dhermain Frederic; Carpentier Antoine F; Frenel Jean Sebastien; Menei Philippe; Bauchet Luc

来源：Neurology, 2015, 85(15): 1325-1331.

DOI：10.1212/WNL.0000000000002014

Objectives:We aimed to study the potential clinical relevance of 9p allelic loss, with or without copy number variation, in 1p/19q codeleted anaplastic oligodendroglial tumors (AOTs).Methods:This study enrolled 216 patients with 1p/19q codeleted AOT. The prognostic value of 9p allelic loss was investigated using a French nation-wide prospective registry, POLA (prise en charge des tumeurs oligodendrogliales anaplasiques) and high-density single nucleotide polymorphism arrays. We validated our results using the Repository of Molecular Brain Neoplasia Data (REMBRANDT) dataset.Results:The minimal common region of allelic loss in chromosome arm 9p was 9p21.3. Allelic loss of 9p21.3, detected in 41.7% of tumors, was associated with shorter progression-free and overall survival rates in univariate (p = 0.008 and p < 0.001, respectively) and multivariate analyses (p = 0.009 and p = 0.009, respectively). This finding was validated in the REMBRANDT dataset in univariate and multivariate analysis (p = 0.01 and p = 0.01, respectively).Conclusion:Our study highlights a novel potential prognostic biomarker in 1p/19q codeleted AOT. Further prospective studies are warranted to investigate our finding.

• 出版日期2015-10-13